Investigation of liver autoantibodies in anticentromere antibody positive patients: A preliminary research

Asli Gamze Sener1*, Celal Bug dacı1, Erkan Yula1, Ilhan Afsar1, Emine Figen Tarhan2, Selcuk Kaya1
1 Izmir Katip Celebi University, Ataturk Training and Research Hospital, Medical Microbiology Laboratory. Izmir, Turkey.
2 Izmir Katip Celebi University, Ataturk Training and Research Hospital, Rheumatology Department, Izmir, Turkey.

Abstract
Background: Anticentromere antibody (ACA) is regarded to be a serological marker specific to CREST (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome. ACA is also found in the sera of patients with autoimmune liver disease. In the present work, anti-soluble liver antigen\liver pancreas antigen (anti-SLA\LP), anti-liver cytosolic antigen 1 (anti-LC1), anti-liver kidney microsomal antigen 1 (anti-LKM1), and anti-mitochondrial antibody M2 (AMA-M2) were evaluated in the patients who had positive anticentromere antibody.

Material and Methods: A total of 39 patients who were positive anticentromere antibody were enrolled in this study undertaken in the Izmir Katip Celebi University, Ataturk Training and Research Hospital, Microbiology laboratory between January and September 2015. Positive anticentromere antibody and liver autoantibodies were analyzed. Anticentromere antibody and liver autoantibodies were studied by indirect immunofluorescence method (IIF) and immunoblotting method (IB), respectively. The patients who had negative anticentromere antibody were used as a control group.

Results: According to the study’s results, positivity was detected in 3 of 39 patients (%7.6) in terms of liver autoantibodies, all of which were AMA-M2. There was no statistically significant difference between ACA and autoimmune liver autoantibodies.

Conclusion: In this study, we reported our preliminary experience to provide evidence for the detection of various autoantibodies as potential diagnostic or prognostic tests. Further studies that contain a broad range of patients may contribute to the field.

Key words: Anticentromere antibody, autoimmune hepatitis, immunofluorescence method.

Introduction
Anticentromere antibody (ACA) is regarded to be a serological marker specific to CREST (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome (1-4). In addition to being present in CREST syndrome, ACA is also detected in the sera of patients with autoimmune liver disease (5).

*Corresponding Author: Asli Gamze Sener. Izmir Katip Celebi University, Ataturk Training and Research Hospital, Medical Microbiology Laboratory. Izmir, Turkey E-mail: agsener@gmail.com Received: Apr 12, 2016. Accepted: Apr 27, 2016 Published Online: May 30, 2016.
Material and methods
A total of 39 patients who had positive anticentromere antibody were enrolled in this study undertaken in the Izmir Katip Celebi University, Ataturk Training and Research Hospital, Microbiology laboratory between January and September 2015. The patients who had negative anticentromere antibody were used as a control group. Positive anticentromere antibody and liver autoantibodies were analyzed retrospectively. Anticentromere antibody and liver autoantibodies were studied by indirect immunofluorescence method (IIF) and immunoblotting method (IB), respectively. Blood samples were collected in serum separator tubes, centrifuged at 2,500 rpm for 10 min. ANA patterns were evaluated by using the HEp-2010/Liver (Monkey) indirect immunofluorescence assay kit (Euroimmun AG, Lübeck, Germany, Lot No. F160318DI). Serum samples were processed in a dilution of 1:100 and conjugated with specific anti-human IgG (Euroimmune AG, Lübeck, Germany, Lot No. F160318DI). The fluorescence intensity was scored at x 400, semi-quantitatively from 1+ to 4+ relative to the intensity of the positive (4+) and negative control. The test result was discarded if the positive control sample failed to show the precise results. There has not been any duplication in assessing the samples. In immunoblotting method liver profile (Euroimmun AG, Lübeck, Germany, Lot No. D150327AD) that contains nylon strips coated with AMA M2, LKM-1, LC-1, SLA/LP antigens along with a control band was used (Figure 1).

Statistical analysis
The difference between variables was analyzed by the statistical Chi square test. Statistical analyses were performed using SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered to be significantly different.

Results
The patients (1 male and 38 females) were aged between 28-80 years, an average of 56.7±11.4 years. Among ACA-positive patients (Figure 2), 16 (41%) systemic sclerosis (SSc), 12 (30.8%) mixed connective tissue disease (MCTD) and 11 (28.2%) CREST diagnoses were detected. AMA-M2 positivity was detected in 3 (7.6%) of 39 ACA-positive patients (Table 1). All of the positive liver autoantibodies were AMA-M2 antibodies and all of the positive patients were women. There was no statistically significant difference between ACA and autoimmune liver autoantibodies (p>0.05).

Table 1. Diagnosis and the number of positive liver autoantibody results of the patients.

<table>
<thead>
<tr>
<th></th>
<th>AMA-M2</th>
<th>LKM-1</th>
<th>SLA/LP</th>
<th>LC-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>CREST syndrome</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MCTD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Discussion
Rheumatoid diseases are multisystem inflammatory diseases related with the development of autoantibodies to several self-antigens. The liver may be one of the organs affected by these diseases (6). ANA molecular targets specific for autoimmune hepatitis (AIH) are not present. A different profile of ANA positivity reminiscent of that found in Systemic Lupus Erythematosus (SLE) has been informed in AIH. However, at least a third of AIH patients positive for ANA do not react with known nuclear targets (7, 8). Himoto et al. have investigated clinical characteristics of patients with autoimmune hepatitis seropositive for anticentromere antibody. In the
study, the scoring system proposed by the International Autoimmune Hepatitis Group was used for diagnosis of AIH. Seropositivity for ACA was evaluated by a discrete speckled pattern on HEp-2 cells by an immunofluorescent method. Seropositivity for ACA was evaluated by a discrete speckled pattern on HEp-2 cells by an immunofluorescent technique. It was informed that eight (17%) of 47 patients with AIH had ACA. Statistically significant differences in age, sex, onset pattern of the disease, progression to hepatic failure and relapse rate were not present between the ACA-AIH and other-AIH groups. They reported that the frequency of concurrent autoimmune diseases in ACA-AIH was remarkably higher than that in other-AIH groups (9).

Lodh et al. presented case report associated with a 49-year-old type 2 diabetes mellitus patient with abdominal pain and black stool for 15 days. They informed that laboratory investigations provided diagnosis of AIH with anticentromere antibodies. The authors reported that screening AIH patients for anticentromere antibody is not obligatory, however, can be regarded, particularly in the presence of disease-related symptomatology for quicker, more reliable diagnosis and optimum management (10). The Committee for Autoimmune Serology of the International Autoimmune Hepatitis Group (IAIHG) supplied guidelines on testing for autoantibodies associated with AIH. According to the guidelines IIF screening on fresh sections of liver, kidney, and stomach from rodents should be the first line screening and the use of the three tissues enabling concurrent detection of almost all the autoantibodies related to liver disease, namely, against smooth muscle antigen (SMA), ANA, LKM1, AMA, and LC1 (11).

You et al. informed that there have been only two reports in the literature considering investigations associated with anti-centromere antibodies in patients with AIH. The studies have indicated the presence of these antibodies at a low frequency of 3% in cases of AIH. The authors reported that the frequency of the discrete speckled pattern of ANA (related to ACA) is increased in AIH patients with ACA, supporting the close association between the AIH and SSc in the Japanese population. They emphasized that no certain consequences can be drawn from these findings, and additional and advanced studies are necessary to examine the relationship between ACA and AIH (12). There are a lot of investigations associated with the clinical significance of ACA in literature (13-16).

**Conclusion**

Although, our current study is a preliminary research, we reported our experience in order to provide evidence for the detection of various autoantibodies as potential diagnostic or prognostic tests. Well-designed further studies that contain a broad range of patients may contribute to the field.

**Ethics Committee Approval:** Ethics Committee approval was received for this study from the ethics committee.

**Informed Consent:** Written informed consent was obtained from patients who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** No conflict of interest was declared by the author.

**Financial Disclosure:** The author declared that this study has received no financial support.

**References**


seropositive for anticentromere antibody. *Hepatol Res* 2010; 40: 786-792.


